JP6256770B2 - Oral care composition, tablets, granular drugs - Google Patents

Description

  The present invention relates to an oral care composition, tablet, and granular drug suitable for maintaining oral health by causing more saliva that exhibits bactericidal and antibacterial effects to be secreted into the oral cavity.

Saliva has the action of keeping the oral cavity moist, smooth digestion of food, and cleaning the oral cavity by a physical or biochemical mechanism. Furthermore, this saliva maintains a constant pH in the oral cavity, and caries by maintaining the pH in the oral cavity to be more neutral by the action of bicarbonate ions (HCO ₃ ⁻ ) in the saliva ( It plays a role in preventing tooth decay. In other words, saliva plays an important role in eating and maintaining oral health.

  However, in recent years, the population of so-called dry mice (xerostomia) in which oral tissues become dry due to a decrease in saliva secretion is increasing. When this dry mouse develops, it is accompanied by symptoms such as difficulty in swallowing food, and a decrease in antibacterial action due to a decrease in the amount of saliva. As a result, bacteria with nutrients from food residues grow and the oral environment deteriorates, causing oral diseases such as dental caries and periodontal disease and the development of bad breath. It can also lead to discomfort, trouble with swallowing and conversation.

  By the way, not only the effects of salivary gland diseases and systemic diseases, but also various causes such as aging and side effects of medications are considered to cause the decrease in saliva volume to develop dry mice. For this reason, it is often difficult to completely eliminate these causes when treating dry mice.

  Under such circumstances, conventional treatments for dry mice include salivary gland consisting of acids, plant extracts, etc., as well as methods of physically stimulating salivary glands by salivary gland massage and chewing to directly promote salivary secretion. A method of promoting secretion of saliva by causing a secretagogue or a food containing them to act in the oral cavity has been proposed (see, for example, Patent Document 1). In addition, as a method for moisturizing the oral cavity, a method has been proposed in which a composition containing a moisturizing component containing a high molecular weight component is included in the oral cavity.

JP 11-71253 A JP 2007-84501 A

  However, according to the above-described prior art, although saliva secretion can be promoted and dry mouth symptoms can be improved, there is a problem that the saliva secretion amount cannot be increased dramatically. In addition, the above-described conventional technology is suitable for use in combination with eye drops or nasal drops, for example, or when a tablet with a saliva secretion component is coated around the tablet to make it easier for people with dry mouth symptoms to take tablets. Not configured. In addition, the above-described conventional technology is not suitable for a case where it is manufactured and sold by mixing with granules or a powdered medicine, or when it is used by mixing with cosmetics, champignons, sprays, gels and the like. Furthermore, the above-described conventional technology is not suitable for a combination with food or beverage.

  In other words, it dramatically improves the dry mouth symptom by dramatically increasing the amount of saliva secretion, and the composition suitable for applying the same composition to various other uses as well as the improvement of the dry mouse. Has long been desired.

  Therefore, the present invention has been devised in view of the above-mentioned problems, and the purpose thereof is to further improve dry mouth symptoms by dramatically increasing the amount of saliva secretion, An object of the present invention is to provide an oral care composition, tablet, and granular drug suitable for developing the same composition to other uses.

  The present invention is a technique which is expected to stabilize lactoferrin and to couple it with calcium ions while blocking the enzyme from being enzymatically degraded. That is, by rapidly binding calcium ions to lactoferrin, the structure is changed to the domain forming the binding site, and the structure is closed. For this reason, lactoferrin is less likely to be structurally destroyed by proteolytic enzymes. That is, calcium ion is a substance that greatly contributes to the stabilization of the structure of lactoferrin.

  The present inventors diligently investigated a calcium substance that can be quickly bound and stabilized with lactoferrin, and identified that calcium oligosaccharide calcium is the substance most contributing to the stabilization of the structure of lactoferrin. .

  The ophthalmic solution according to the present invention contains an ophthalmic drug component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.0. It is characterized by containing 01 to 10%.

  The nasal solution according to the present invention contains a nasal drug component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: It contains 0.01 to 10%.

  The cosmetic according to the present invention contains a cosmetic ingredient and an auxiliary ingredient, and the auxiliary ingredient is in mass% with respect to the total mass of the auxiliary ingredient, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.0. It is characterized by containing 01 to 10%.

  The tablet which concerns on this invention contains a chemical | medical agent component and an auxiliary component, The said auxiliary component is the mass% with respect to the said auxiliary component total mass, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10 %.

  The powder or granular drug according to the present invention contains a drug component consisting of powder or granules, and an auxiliary component, and the auxiliary component is phosphorylated oligosaccharide in mass% with respect to the total mass of the auxiliary component. It is characterized by containing calcium: 1-30% and lactoferrin: 0.01-10%.

  The skin or hair cleaning composition according to the present invention contains a cleaning component and an auxiliary component, and the auxiliary component is a mass% based on the total mass of the auxiliary component, and phosphorylated oligosaccharide calcium: 1 to 30. %, Lactoferrin: 0.01 to 10%.

  The hair treatment material according to the present invention contains a hair treatment component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0. .01 to 10%.

  The food composition according to the present invention contains an edible component and an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.0. It is characterized by containing 01 to 10%.

  The beverage composition according to the present invention contains a beverage component and an auxiliary component, and the auxiliary component is a mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0. .01 to 10%.

  The seasoning composition which concerns on this invention contains a seasoning component and an auxiliary component, The said auxiliary component is the mass% with respect to the said auxiliary component total mass, phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: It contains 0.01 to 10%.

  The oral care composition according to the present invention is an oral care composition that promotes health in the oral cavity by being contained in the oral cavity, and is in mass% relative to the total mass of the composition, phosphorylated oligosaccharide calcium: 1 to 30%, Lactoferrin: 0.01 to 10%, magnesium compound: containing 1 to 5% in terms of magnesium.

  The oral care composition according to the present invention is an oral care composition that promotes health in the oral cavity by being contained in the oral cavity, and is in mass% relative to the total mass of the composition, phosphorylated oligosaccharide calcium: 1 to 30%, It is characterized by containing lactoferrin: 0.01 to 10% and sucralose: 1 to 5%.

  The toothache relieving agent according to the present invention contains an auxiliary component, and the auxiliary component is in mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%, Lactoperoxidase: It contains 1 to 20%.

  According to the present invention having the above-described configuration, by including it in the oral cavity of a subject, the phosphorylated oligosaccharide calcium and lactoferrin contained in this oral care composition act synergistically due to the presence of each other, A large amount of saliva will be secreted. At this time, secretion of saliva will be further promoted by containing the above-mentioned sodium bicarbonate, potassium carbonate, or potassium bicarbonate.

  In this way, the secretion of saliva in the oral cavity is dramatically promoted, so that the digestion of food is helped and the self-cleaning action of washing away the food residue in the oral cavity is enhanced. In addition, the bactericidal action in the oral cavity is also exhibited, and furthermore, the pH in the oral cavity is maintained so as to be more alkaline, it is possible to prevent the occurrence and progression of caries, and the action of remineralization Can also be exhibited. In addition, the oral care composition to which the present invention is applied can alleviate the symptoms of dry mice that frequently appear in the elderly and the like by promoting the secretion of saliva in the oral cavity.

  In addition, the present invention has a configuration suitable for use in combination with, for example, eye drops or nasal drops, or when it is easy to drink tablets even for people with dry mouth symptoms by coating the secretion component of saliva around the tablets. can do. In addition, the present invention can be configured to be suitable for the case where it is manufactured and sold by mixing it with granules or powdered drugs, or when it is used by mixing with cosmetics, champlins, sprays, gels and the like. Moreover, this invention can be set as the structure suitable in the case of combining with a food and a drink.

  That is, according to the present invention having the above-described configuration, the dry mouth symptom is dramatically improved by dramatically increasing the amount of saliva secreted, and the same composition can be used to improve not only the dry mouse but also other It becomes possible to set it as the structure suitable when applying to various uses.

  In particular, in the present invention, it is possible to promote the secretion of a large amount of saliva, so even in places where there is no water such as disaster areas, by including this in the mouth, the occurrence of caries without brushing teeth and Progression can be prevented. In addition, people who have difficulty brushing their teeth, such as the elderly and the physically handicapped, can prevent the occurrence and progression of dental caries without brushing their teeth by including the oral care composition to which the present invention is applied in the mouth. It becomes possible.

It is a figure for demonstrating the example in the case of applying this invention to a tablet.

  In order to solve the above-mentioned problems, the present inventors have focused on the action expressed by saliva and invented an oral care composition capable of secreting a large amount of this to promote health maintenance in the oral cavity. did. The main effects expressed by saliva are as follows.

  Saliva contains the digestive enzyme amylase. This amylase develops an effect of facilitating absorption in the body by decomposing carbohydrates contained in food. Saliva has an effect of helping food digestion by including such an amylase as an enzyme.

  Moreover, a food bolus of an appropriate size can be generated by mixing food in the oral cavity with saliva. For this reason, saliva has an effect of helping to swallow food. Saliva also exerts a so-called self-cleaning action to wash away the meal in the oral cavity. That is, the amount of saliva secreted by chewing well increases and the self-cleaning action is enhanced.

  Saliva also contains lysozyme that exerts antibacterial action against bacteria entering from the outside through the mouth and nose. Moreover, the saliva also serves to wash out the inside of the oral cavity, and a large amount of saliva is secreted, so that dirt in the oral cavity can be removed and thus bad breath can be prevented.

Saliva also plays a role of keeping the pH in the oral cavity constant, so-called buffering action. By the action of bicarbonate ions (HCO ₃ ⁻ ) in saliva, the pH in the oral cavity is maintained to be more neutral. In general, caries (decayed tooth) starts with so-called demineralization, where the pH in the oral cavity tends to become acidic due to the generation of a large amount of acid in the plaque and the calcium and minerals on the tooth surface begin to dissolve. Become. However, since a large amount of saliva is secreted, the oral cavity quickly returns to neutrality based on the buffering action of saliva itself.

  Further, saliva exhibits a so-called remineralization action that replenishes and repairs calcium and minerals on the tooth surface dissolved by acid.

  The present inventors diligently studied the conditions that allow these saliva to exert their actions more suitably. As a result, it was experimentally verified that saliva can be secreted in a larger amount by including an oral care composition comprising the following components and including it in the oral cavity of the subject. As a result, the inventors have newly found that saliva secretion can be dramatically increased based on the synergistic effect of mixing phosphorylated oligosaccharide calcium and lactoferrin. This phosphorylated oligosaccharide calcium is a substance that is hardly soluble in water, whereas lactoferrin is a substance that is easily soluble in water. That is, it is based on an unprecedented idea of mixing phosphorylated oligosaccharide calcium and lactoferrin having different hydration properties into one oral care composition.

  That is, the oral care composition according to the present invention is an oral care composition that promotes health in the oral cavity by being contained in the oral cavity, and is phosphorylated oligosaccharide calcium: 1% by mass relative to the total mass of the composition: -30%, lactoferrin: 0.01 to 10%. This oral care composition may further contain a magnesium compound: 1 to 5% in terms of magnesium. The oral care composition may contain sucralose: 1 to 5%. The oral care composition to which the present invention is applied may contain sodium bicarbonate: 1 to 20%, or may contain 1 to 5% potassium carbonate or potassium bicarbonate. Good.

  In the oral care composition to which the present invention is applied, the remainder may contain any one or more of indigestible dextrin, jumpinion extract powder, xylitol, fragrance, fine silicon dioxide, calcium stearate and the like.

  Hereinafter, the reasons for limiting the components and content of the oral care composition to which the present invention is applied will be described. In addition, the content of each component is expressed by mass% with respect to the total mass of the composition, and when expressing the mass%, it is simply expressed as%.

Phosphorylated oligosaccharide calcium: 1-30%
Phosphorylated oligosaccharide calcium is a starch-derived component derived from Hokkaido potatoes. Potato starch has a portion to which a phosphate group is bonded, and the starch is extracted and purified by allowing an enzyme to act on the starch to prepare a calcium salt, which is phosphorylated oligosaccharide calcium. This phosphorylated oligosaccharide calcium causes the action of secreting a large amount of saliva by being contained in the oral cavity. In addition to exerting the function as a calcium source, this phosphorylated oligosaccharide calcium does not become a nutrient source for mutans streptococcus, a cariogenic bacterium, and further reduces the pH in the oral cavity by a buffering action. The function to suppress can be demonstrated. Phosphorylated oligosaccharide calcium can promote tooth remineralization by enhancing dissolved calcium ions in saliva.

  When the content of phosphorylated oligosaccharide calcium is less than 1%, the functions inherently possessed by phosphorylated oligosaccharide calcium cannot be exhibited, and the above-described effects cannot be achieved. On the other hand, when the content of phosphorylated oligosaccharide calcium exceeds 30%, the effect is saturated, and the raw material cost is increased by containing a large amount thereof. If a large amount of phosphorylated oligosaccharide calcium is added to exceed 30%, it becomes extremely toxic to infants. For this reason, content of phosphorylated oligosaccharide calcium shall be 1-30%.

Lactoferrin: 0.01-10%
Lactoferrin is an iron-binding glycoprotein having a molecular weight of about 80,000 that is widely distributed in the animal body. Lactoferrin is made from mammals (eg, humans, cows, goats, sheep, horses, etc.) colostrum, transitional milk, normal milk, end milk, or processed milk products of skim milk, whey, etc. For example, by using a known separation / purification method such as ion exchange chromatography, it is possible to use those obtained by separation from the raw materials. This lactoferrin may be produced from a plant (tomato, rice, tobacco) or may be obtained by genetic recombination. Furthermore, lactoferrin may be a commercially available product or can be prepared and used by a known method. Lactoferrin can be used alone or in combination of two or more. Such a lactoferrin causes an action of secreting a large amount of saliva by being included in the oral cavity.

  The core functions that this lactoferrin can play include introduction of immune tolerance, enhancement of foreign body recognition, inhibition of angiogenesis, enhancement of opioid action, and the like. The introduction of immune tolerance can be expected to improve autoimmune diseases and various allergies. Further, by enhancing foreign object recognition, for example, an improvement effect can be expected for infectious diseases, particularly opportunistic infections. In addition, lactoferrin has an effect of inhibiting angiogenesis induced by inflammation, and is therefore effective for angiogenic diseases such as cancer. On the other hand, lactoferrin enhances the effect of endogenous opioids called intracerebral narcotics, and thus can also exert an analgesic effect on pain.

  In addition to the saliva secretion effect described above, lactoferrin can also exert an effect on conjunctival mucosa repair and lacrimal gland rejuvenation. Therefore, the effect of improving so-called dry eye can be expected by instilling such lactoferrin. Lactoferrin may also be able to treat and prevent neurodegenerative diseases such as Alzheimer's disease.

  If the content of lactoferrin is less than 0.01%, the function inherently possessed by lactoferrin cannot be exhibited, and the above-described desired effect cannot be achieved. On the other hand, when the content of lactoferrin exceeds 10%, the effect is saturated, and the raw material cost is increased by containing a large amount thereof. In addition to this, when the content of lactoferrin exceeds 10%, the blood sugar level of the patient who has taken it increases. For this reason, content of lactoferrin shall be 0.01-10%.

Sodium bicarbonate: 1-20%
Sodium bicarbonate (sodium bicarbonate) is commonly referred to as baking soda. As an additive such as calf powder and soft drinks, in various food fields, as well as in pharmaceutical fields such as artificial dialysates and gastrointestinal drugs, fire extinguishing agents, Widely used as bathing agent, cleaning agent, etc. Inclusion of such sodium bicarbonate in the oral cavity causes an action to secrete a large amount of saliva.

If the content of sodium bicarbonate is less than 1%, the functions inherently possessed by sodium bicarbonate cannot be exhibited, and the above-mentioned desired effects cannot be achieved. On the other hand, when the content of sodium bicarbonate exceeds 20%, the effect is saturated. For this reason, content of sodium bicarbonate shall be 1-20%.

  Incidentally, the content of this sodium bicarbonate is preferably 6 to 16%, and more preferably 10 to 16%, in order to achieve the desired effect. As an example of this desirable sodium bicarbonate, the reason that the upper limit is 16% is that when sodium bicarbonate exceeding 16% is added, nausea may be felt, resulting in a composition that tends to vomit.

Potassium carbonate: 1-5%
Potassium carbonate has long been a general-purpose component in many fields such as pharmaceuticals, foods, and cosmetics, and is blended in pharmaceuticals as an antacid or acidosis inhibitor, or used as a component of an oral hydration agent. In addition, potassium carbonate can also function as a buffering agent that makes saliva alkaline or maintains an alkaline state. Inclusion of such potassium carbonate in the oral cavity causes an action to secrete a large amount of saliva.

  If the content of potassium carbonate is less than 1%, the functions originally possessed by potassium carbonate cannot be exhibited, and the above-mentioned desired effects cannot be achieved. On the other hand, when the content of potassium carbonate exceeds 5%, the effect is saturated. For this reason, content of potassium carbonate shall be 1-5%. In addition, you may make it add potassium hydrogencarbonate as an alternative of potassium carbonate.

  In addition, in this invention, you may contain the following component as needed.

Phosphate source compound: 1-3%
The phosphoric acid source compound is a compound selected from the group consisting of phosphoric acid, sodium phosphate, potassium phosphate, polyphosphoric acid and cyclic phosphate. Among them, polyphosphoric acid is a compound formed by condensation of two or more phosphoric acids, and is frequently used as food excipients, discoloration inhibitors and the like. The degree of polymerization in the polyphosphoric acid is arbitrary as long as it is 2 or more. For example, it is 2 or more and 10 or less. Examples of polyphosphoric acid include pyrophosphoric acid, triphosphoric acid, trimetaphosphoric acid, tetrametaphosphoric acid, and cyclopolyphosphoric acid. Examples of cyclic phosphoric acid include hexametaphosphoric acid. Polyphosphoric acid can suppress a decrease in intestinal barrier function and can exhibit a function of restoring the intestinal barrier function. Polyphosphate is synthesized from ATP by polyphosphate kinase in microorganisms such as E. coli. By including such polyphosphoric acid in the oral cavity, an action of secreting a large amount of saliva is caused. The phosphate source compound is desirably in the range of 1 to 3%.

Magnesium compound: 1 to 5% in terms of magnesium
Examples of the magnesium compound include magnesium carbonate and magnesium sulfate. Among them, magnesium carbonate is mainly used as a toothpaste abrasive or antacid. By mixing such magnesium carbonate, an effect of secreting a large amount of saliva is caused. The content of the magnesium compound is defined as a magnesium conversion value. This magnesium conversion value is mass% based on the mass of Mg contained in the compound. When the magnesium conversion value is less than 1%, such saliva secretion effect cannot be achieved. On the other hand, if the magnesium conversion value exceeds 5%, the effect is saturated. For this reason, a magnesium compound shall be 1-5% in magnesium conversion value.

Sucralose: 1-5%
Sucralose is one of the artificial sweeteners born from sucrose. Sucralose has about 600 times the sweetness of sucrose, is easily dissolved in water, and has excellent stability. In addition, sucralose has a mild sweetness similar to that of sugar, but it is not digested and absorbed as a carbohydrate in the body like sugar, and therefore has no physiological heat. For this reason, sucralose is applied to various beverage compositions and food compositions including soft drinks and ice creams. The sucralose exerts a mellow sweetness that produces a large amount of saliva. When the sucralose content is less than 1%, such saliva secretion effect cannot be achieved. On the other hand, when the content of sucralose exceeds 5%, the effect is saturated, and the raw material cost due to the inclusion of a large amount thereof increases. Therefore, the sucralose content is 1 to 5%.

The remainder of the indigestible dextrin is roasted dextrin obtained by acidification and / or heating of starch derived from plants such as corn, wheat, rice, beans, potatoes, tapioca, etc. And / or water-soluble dietary fiber that has been desalted and decolorized as necessary after treatment with glucoamylase, which has indigestible characteristics. In the oral care composition to which the present invention is applied, it is used as a bulking agent in the case of constituting as a tablet, and the content thereof is not particularly limited and is added in an appropriate amount.

  Jumpinion extract powder is a component extracted from mushrooms, and is added in an appropriate amount to eliminate bad breath and other odors.

  Xylitol is a pentose sugar alcohol that exists in nature, and what is added in the present invention may be any known source. By adding this xylitol, it becomes possible to make it easy to drink when the oral care composition is constituted as a tablet. The content of xylitol is not particularly limited, and an appropriate amount is added.

  A fragrance | flavor is obtained by mixing many natural fragrance | flavors extracted from various plants and some animals, or the synthetic fragrance | flavor chemically synthesize | combined. For example, it becomes possible to make it easy to drink when the oral care composition is constituted as a tablet by adding an orange fragrance. In addition, by adding a menthol fragrance, it is possible to express a refreshing sensation when consumed. The content of the fragrance is not particularly limited, and an appropriate amount is added.

  Fine silicon dioxide is a fine particle obtained by decomposing sodium silicate with hydrochloric acid or sulfuric acid, and is added in an appropriate amount to adjust the hardness, but the addition is not essential.

  Calcium stearate is a calcium salt of stearic acid and palmitic acid, which uses palm-derived fatty acids that have the effect of increasing the lubricity, fluidity and preventing caking of powdered products, or emulsifying the product structure and increasing the viscosity. It is. The content of calcium stearate is not particularly limited, and an appropriate amount is added.

  The oral care composition to which the present invention is applied may be embodied by solidifying each component having the above-described content as a tablet or powder, or may be embodied as a liquid. There may be.

  By including such an oral care composition to which the present invention is applied in the oral cavity of a subject, the phosphorylated oligosaccharide calcium and lactoferrin contained in this oral care composition act synergistically due to the presence of each other. As a result, a larger amount of saliva is secreted. In addition, since the calcium content of calcium phosphate oligosaccharide is quickly bound to lactoferrin and lactoferrin is less likely to be structurally destroyed by the proteolytic enzyme, it can be structurally stabilized.

  As a result, drastic secretion of saliva in the oral cavity occurs, and the symptoms of dry mice can be alleviated. At this time, secretion of saliva will be further promoted by containing the above-mentioned sodium bicarbonate, potassium carbonate or potassium bicarbonate, magnesium carbonate, and sucralose.

  In this way, the secretion of saliva in the oral cavity is promoted, so that the digestion of food is helped, and the self-cleaning action of washing away the food residue in the oral cavity is enhanced. In addition, bactericidal action in the oral cavity is also demonstrated, and furthermore, the pH in the oral cavity will be maintained to be more neutral, it becomes possible to prevent the occurrence and progression of caries, and remineralization It is also possible to exert the action.

  In particular, in the present invention, it is possible to promote the secretion of a large amount of saliva, so even in places where there is no water such as disaster areas, by including this in the mouth, the occurrence of caries without brushing teeth and Progression can be prevented. In addition, people who have difficulty brushing their teeth, such as the elderly and the physically handicapped, can prevent the occurrence and progression of dental caries without brushing their teeth by including the oral care composition to which the present invention is applied in the mouth. It becomes possible.

  In addition, the oral care composition to which the present invention is applied can alleviate the symptoms of dry mice that frequently appear in the elderly and the like by promoting the secretion of saliva in the oral cavity. Moreover, the oral care composition which consists of the structure mentioned above may be applied as a toothache relieving agent for relieving toothache. In addition, detailed embodiment in the case of applying to a toothache relieving agent is mentioned later.

  In addition, this invention is not limited to the case where it is comprised only with the oral care composition single-piece | unit which consists of a compounding ratio of the component mentioned above. You may apply to the eye drop with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When it is embodied as an eye drop, it is embodied as an eye drop solution containing an auxiliary component composed of the blending ratio of the oral care composition described above and an eye drop component contained in a normal eye drop. As the eye drop component, for example, an anti-inflammatory agent, a vitamin agent, a vasoconstrictor, an antihistamine, a mydriatic agent, a miotic agent, an intraocular pressure-lowering agent, a cataract treatment agent, a steroid hormone agent, an antibiotic, a local anesthetic agent, hyperemia Examples include a removal component, an amino acid component, an antibacterial component, and the like, but are not limited thereto, and any other eye drop component may be mixed. The eye drop solution contains water and preservatives in addition to the eye drop component.

  The auxiliary component is contained in an amount of 0.01 to 10% by mass% based on the total mass of the eye drop solution. Incidentally, the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component may be configured to be instilled separately. In such a case, an ophthalmic solution consisting of phosphorylated oligosaccharide calcium and an ophthalmic component if necessary is placed in one container, and an ophthalmic solution consisting of lactoferrin and an ophthalmic component if necessary is placed in another container. . Then, instillation is performed with the eye drop solution in one of the containers, and after a while, instillation is performed with the eye drop solution in the other container. Thereby, the time of instillation of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin in the eyes can be prevented.

  According to the ophthalmic solution having the above-described configuration, so-called dry eye can be improved by the repair action of the conjunctival mucosa and the rejuvenation action of the lacrimal gland cells by lactoferrin. In addition, according to the present invention, the liquid oral care composition itself may be embodied as an eye drop solution.

  Moreover, in this invention, it may be applied to the nasal spray in which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When embodied as a nasal drop, it is embodied as a nasal drop containing an auxiliary component comprising the blending ratio of the oral care composition described above and a nasal drop component contained in a normal nasal drop. Examples of the nasal spray component include a vasoconstrictor, a vasodilator, an antihistamine, a steroid and the like, but are not limited thereto, and any other nasal spray component may be mixed.

  An auxiliary component contains 0.01 to 10% by mass% with respect to the total mass of nasal drops. Incidentally, the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component may be configured to nasally separate from each other. In such a case, a nasal solution composed of phosphorylated oligosaccharide calcium and, if necessary, a nasal drug component is placed in one container, and a nasal solution composed of lactoferrin and, if necessary, a nasal drug component, in another container. Put in. Then, the nasal drop is performed with the nasal solution in one of the containers, and after a while, the nasal solution is performed with the nasal solution in the other container. Thereby, the nasal drop time of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin in the nose can be prevented.

  According to the nasal solution having the above-described configuration, lactoferrin passes through the blood-brain barrier from the nasal capillaries through the nasal nose, causing calcium ions associated with lactoferrin to spread into the brain blood. Alzheimer's disease can be improved by eliminating the lack of calcium ions in the brain blood. In addition, according to the present invention, the liquid oral care composition itself may be embodied as a nasal solution.

  Moreover, in this invention, you may apply to the cosmetics with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When it is embodied as a cosmetic, it is embodied as a cosmetic containing an auxiliary component composed of the blending ratio of the above-described oral care composition and a cosmetic component contained in a normal cosmetic. This cosmetic is a foundation or cream for application to the skin, and other cosmetic liquids. Cosmetic ingredients include so-called whitening ingredients such as arbutin, fullerene, tranexamic acid, hydroquinone, yokuinin extract, and placenta extract. Ascorbyl acid sodium, ascorbyl phosphate Mg, ascorbyl tetrahexyldecanoate, ascorbyl palmitate, so-called vitamin C derivatives, hyaluronic acid sodium, water-soluble collagen, placenta extract, ceramide 2, ceramide 3, ceramide 6 and other moisturizing ingredients, astaxanthin Anti-aging ingredients such as coenzyme Q10, EGF (human oligopeptide), platinum nanocolloid, retinoic acid tocopheryl, retinol, etc., but are not limited to these, and any other cosmetic ingredients may be mixed It may be the one.

  The auxiliary component is contained in an amount of 0.01 to 20% by mass% based on the total mass of the cosmetic. Incidentally, the phosphorylated oligosaccharide calcium and lactoferrin in the auxiliary component may be configured to be applied to the skin separately from each other. In such cases, the phosphorylated oligosaccharide calcium and, if necessary, cosmetics comprising cosmetic ingredients are placed in one container, and the lactoferrin and, if necessary, cosmetics comprising cosmetic ingredients are placed in another container. . Then, the cosmetic in one of the containers is applied to the skin, and after a while, the cosmetic in the other container can be applied to the skin for treatment. Thereby, the makeup time of phosphorylated oligosaccharide calcium and lactoferrin can be shifted, and mixing of phosphorylated oligosaccharide calcium and lactoferrin on the surface of the skin can be prevented.

  According to the cosmetic composition having the above-described structure, the calcium ion of phosphorylated oligosaccharide calcium is combined with lactoferrin to cause penetration into the horny layer of the skin and acts as a calcium ion localized in the epidermal granule layer. And the localization of calcium in the epidermis can be improved. As a result, symptoms such as rough skin, dullness, and dry skin can be improved. In addition, according to the present invention, the cream-type or powder-type oral care composition itself may be embodied as a cosmetic.

  Moreover, in this invention, you may apply to the tablet with which the component which consists of a mixing | blending ratio of the oral care composition mentioned above was mixed. When it is embodied as a tablet, it is embodied as a tablet containing an auxiliary component composed of the blending ratio of the oral care composition described above and a drug component as an active ingredient contained in a normal tablet. This tablet has, for example, an antipyretic analgesic component, expectorant component, anti-inflammatory component, sedative component, antacid component, vitamin and other nourishing tonic component, Kampo formulation, caffeine and other drowsiness prevention Min, anti-vertigo component, anti-histamine component, anti-cholinergic component, local anesthetic component, bactericidal disinfectant component, healthy stomach component, digestive component, gastric mucosa protection / restoration component, antipruritic component, tissue repair component, hemostatic component, vasoconstrictor component Etc. However, the drug component is not limited to these, and any other component may be mixed. Examples of the tablet other than the active ingredient include a bulking agent, a binder, and a lubricant.

  The auxiliary component is contained in an amount of 1 to 40% by mass% based on the total mass of the tablet. In such a case, as shown in FIG. 1, it may be configured as a tablet 10 in which the auxiliary component 2 is coated on the surface of the nucleating agent 1 containing the drug component. When the auxiliary component 2 is coated on the surface of the nucleating agent 1, the nucleating agent 1 may be exposed because there are portions that are not completely covered by the auxiliary component 2. That is, the auxiliary component 2 may cover at least a part of the nucleating agent 1. In addition to the form shown in FIG. 1, the auxiliary component and the drug component may be mixed with each other to constitute one tablet.

  By including such a tablet in the mouth, the phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other and secrete a larger amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, and even a person with dry mouth symptoms can easily take tablets through saliva.

  Moreover, in this invention, you may apply to the powdery medicine or granular medicine with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. Specifically, a powdery auxiliary ingredient composed of the above-mentioned mixing ratio of the oral care composition and a powdery medicine containing a pharmaceutical ingredient containing an active ingredient made of powder, or an auxiliary ingredient in the form of granules It is embodied as a granular drug containing a drug component including an active ingredient composed of granules. These powdered drugs or granular drugs may be encapsulated in a capsule and distributed and used. Incidentally, since this drug component is the same as the above-described tablet, the following description is omitted by citing such description.

  The auxiliary component is contained in an amount of 0.1 to 40% by mass% based on the total mass of the powder or granular drug. By including such a powder or granular medicine in the mouth, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other, and saliva is secreted in a larger amount. As a result, drastic secretion of saliva in the oral cavity occurs, and even a person with dry mouth symptoms can easily take a powder or granular drug through saliva.

  Further, in the present invention, it is applied to a skin or hair cleaning composition such as a hair shampoo, body shampoo, cleansing, facial cleansing foam, etc., in which the components comprising the blending ratio of the oral care composition described above are mixed. May be. When embodied as a cleaning composition for skin or hair, skin containing an auxiliary component comprising the above-mentioned blending ratio of the oral care composition and a cleaning component contained in normal skin or hair detergent Or it is embodied as a cleaning composition for hair. This skin or hair cleaning composition is composed of, for example, powder, solid, paste, or liquid. In the following example, a case where the liquid is constituted will be described as an example. The cleaning component is mainly composed of water and a surfactant. Surfactants include higher alcohol surfactants, amino acid surfactants, betaine surfactants (amphoteric surfactants), nonionic surfactants (nonionic surfactants), and natural surfactants. Can be mentioned. In addition to this cleaning component, silicon, menthol, moisturizing components, soap, cocoon oil, and the like are also added.

  The auxiliary component is contained in an amount of 0.1 to 10% by mass% based on the total mass of the skin or hair cleaning composition. By washing the hair and skin with such a skin or hair cleaning composition, the action of feeding calcium ions and lactoferrin into the inside of the hair and the epidermal layer of the skin can occur, and the quality of the hair and skin can be improved. It becomes.

  Moreover, in this invention, you may apply to hair treatment materials, such as the rinse, the conditioner, the treatment, and the hair-styling (including gel, mousse, spray), etc. with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. . When it is embodied as a hair treatment material, it is constituted by containing an auxiliary component and a hair treatment component comprising the blending ratio of the oral care composition described above. The hair treatment component is composed of, for example, powder, solid, paste, or liquid. In the following example, a case where the liquid is constituted will be described as an example. Hair treatment ingredients include rinse, conditioner, treatment, purified water, reduced water, glycerin, squalane, moisturizer, oil, aminoethylaminopropylmethicone dimethicone, higher alcohol, plant seed oil, medform Estolides, cholesterol, aloe extract, olive oil fatty acid glycerin, biohyaluronic acid and the like. The hair treatment component is composed of liquid oil, polymer, solid oil, surfactant, alcohol, moisture, propellant (gas), fragrance, preservative, stabilizer, silicon, etc. Has been.

  The auxiliary component is contained in an amount of 0.1 to 10% by mass% based on the total mass of the hair treatment material. By treating the hair with such a hair treatment material, an action of fixing lactoferrin and phosphorylated oligosaccharide calcium ions to the hair root by electrolysis of an ion channel occurs, and it becomes possible to perform effective hair treatment.

  Moreover, in this invention, you may apply to the foodstuff composition with which the component which consists of a mixture ratio of the oral care composition mentioned above was mixed. When embodied as a food composition, it is embodied as a food composition containing an auxiliary component composed of the blending ratio of the oral care composition described above and an edible component constituting a normal food or confectionery. . This food composition is composed of nutrients such as proteins, lipids, carbohydrates, calcium, vitamins, and carotene. The confectionery here includes, for example, luxury items such as gum and candy.

  The auxiliary component is contained in an amount of 0.01 to 30% by mass% based on the total mass of the food composition. In addition to normal nutrition, such a food composition enables the action of lactoferrin to transcend the blood-brain barrier into the cerebrospinal fluid and treat neurodegenerative diseases such as Alzheimer's disease. It becomes possible to prevent. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, and even a person with dry mouth symptoms can make a food that is easy to eat through saliva. Furthermore, it is possible to treat the meal remaining in the oral cavity after the meal through saliva with increased secretion amount, which contributes to the health promotion in the oral cavity.

  Moreover, in this invention, you may apply to the drink composition with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When embodied as a beverage composition, it is embodied as a beverage composition containing an auxiliary component composed of the above-mentioned blending ratio of the oral care composition and a beverage component constituting a normal beverage. This beverage composition is composed of soft drinks, carbonated drinks, alcoholic beverages, etc., and is composed of moisture, coffee, fragrance, colorant, sugar, vitamin C, salt, fruit extract, alcohols and the like. .

  The auxiliary component is contained in an amount of 0.01 to 20% by mass% based on the total mass of the beverage composition. Such a beverage composition makes it possible to exert the action of translocating to the cerebrospinal fluid through the blood-brain barrier of lactoferrin in addition to normal water and nutrient intake, and neurodegenerative diseases such as Alzheimer's disease Can be treated and prevented. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, which contributes to health promotion in the oral cavity.

  Moreover, in this invention, you may apply to the seasoning composition with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When it is embodied as a seasoning composition, it is embodied as a seasoning composition containing an auxiliary component consisting of the blending ratio of the oral care composition described above and a seasoning component constituting a normal seasoning. The This seasoning composition is composed of liquid, solid, powder, etc., in addition to salt, soy sauce, sugar, vinegar, miso, chili oil, dressing, mayonnaise, ketchup, tabasco, pepper, cinnamon chili, It is represented by mirin, cooked liquor, Japanese-style seasoning (tsuyu, ponzu), but other than this, it may be composed mainly of amino acids such as umami seasoning. .

  The auxiliary component is contained in an amount of 0.01 to 10% by mass% based on the total mass of the seasoning composition. With such a seasoning composition, it is possible to exert the action of lactoferrin to transcend the blood-brain barrier to cerebrospinal fluid and to treat and prevent neurodegenerative diseases such as Alzheimer's disease It becomes. In addition, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva. As a result, drastic secretion of saliva occurs in the oral cavity, which contributes to health promotion in the oral cavity.

  Moreover, in this invention, you may apply to the tooth pain relieving agent with which the component which consists of a compounding ratio of the oral care composition mentioned above was mixed. When it is embodied as a tooth pain relieving agent, it is embodied as a composition containing an auxiliary component composed of the above-mentioned blending ratio of the oral care composition and a normal main component. However, the tooth pain relieving agent may be composed only of auxiliary components without adding the main component.

  The main components include antipyretic analgesic component, expectorant component, anti-inflammatory component, sedative component, antacid component, vitamin and other nourishing tonic component, Chinese medicine formulation, antihistamine component, anticholinergic component, local anesthetic component, bactericidal disinfectant component, healthy Active ingredients such as gastric components, digestive components, gastric mucosa protection / restoration components, antipruritic components, tissue repair components, hemostatic components, vasoconstriction components, and the like can be mentioned. However, the main component is not limited to these, and any other component may be mixed. Examples of the tablet other than the active ingredient include a bulking agent, a binder, and a lubricant.

  In the case of actually embodying the tooth pain relieving agent to which the present invention is applied, it is composed of tablets, granules, liquids, etc., but is not limited thereto, for example, foods, beverages, confectionery such as gum and candy It may be included in the class. In such a case, the main component is composed of the edible component and the beverage component described above. This edible component also includes a gum component that is discarded after chewing.

  Moreover, when embodying the tooth pain relieving agent to which the present invention is applied, it may be embodied in toothpaste, dental gel or the like. In such a case, the main component is a main agent such as sorbite liquid, a base material such as water, a granule, a wetting material such as silicic anhydride, a medicinal component such as zeolite or sodium monofluorophosphate, other foaming agents, flavoring agents, and coloring. The ingredients are added.

  The auxiliary component is contained in an amount of 1 to 100% by mass% based on the total mass of the tooth pain reliever. Of course, by including such a toothache relieving agent in the mouth, phosphorylated oligosaccharide calcium and lactoferrin act synergistically due to the presence of each other to secrete a large amount of saliva.

  In addition to this, phosphorylated oligosaccharide calcium dissolves in saliva in the oral cavity and changes to calcium phosphate. This calcium phosphate is the enamel component itself that constitutes the teeth. For this reason, when this changed calcium phosphate enters the carious part of the enamel of the tooth, it acts as if the carious part is embedded and the lid is covered, so-called remineralization progresses. . As a result, it is possible to prevent food, food, and bacteria from entering the carious portion from the oral cavity. Thereby, toothache can be prevented.

  Further, according to the present invention, lactoferrin further acts on the inflamed part of caries, inflamed gums and gums, and further on edema teeth, and acts to reduce inflamed bacteria. Become. As a result, toothache is further cured.

  That is, according to the present invention, it is possible to improve the pain of the carious portion, gingival inflammation, swelling of the gums, improvement of wobble of edema, periodontal disease such as stomatitis, and remineralization. It becomes possible to treat caries per se. In addition, in the present invention, since toothache can be alleviated and caries can be simultaneously treated by simply including it in the oral cavity, a treatment and treatment that should be usually performed in a dental clinic is included in the mouth. This can be realized with an extremely simple operation. In particular, salivary secretion by the above-mentioned phosphorylated oligosaccharide calcium and lactoferrin is further promoted, so that tooth remineralization is promoted.

  Furthermore, according to this invention, it may contain lactoperoxidase: 1-20% by mass% with respect to the auxiliary component total mass. Like lactoferrin, this lactoperoxidase is a biological defense component contained in saliva and milk and is an enzyme that exhibits antibacterial action against various bacteria such as periodontal disease bacteria. When this lactoperoxidase is less than 1% by mass with respect to the total mass of auxiliary components, the antibacterial action cannot be expressed more effectively. On the other hand, when this lactoperoxidase is more than 20% in mass% with respect to the total mass of auxiliary components, the effect is saturated. For this reason, in order to suitably express the antibacterial action by this lactoperoxidase, it is desirable to contain 1 to 20% by mass% relative to the total mass of the auxiliary components.

  In addition, although this invention demonstrated taking the case where it comprised by the two-component system of a main component (a pharmaceutical ingredient, an edible ingredient, a component for drinks), and an auxiliary component in any embodiment, it is limited to this. It is not something. That is, you may make it comprise only an auxiliary component. In such a case, any chemical solution, cosmetic, food composition, beverage composition, etc. is composed of 100% of the auxiliary ingredients, and the phosphorylated oligosaccharide calcium and lactoferrin constituting the auxiliary ingredients are mixed in the above-described ratio. Will be. Moreover, also when comprised by the two-component system of a main component and an auxiliary component, the content rate of the auxiliary component is not limited to the range mentioned above, If it is between 0.1 to 100% You may be comprised by what content ratio.

  The present invention will be specifically described below with reference to test methods, examples and comparative examples used in the present invention, but the present invention is not limited to these examples. In the following examples, when only% is described, it indicates mass%.

  In the present invention, as shown in Tables 1 and 2, sample tablets obtained for experimental investigation were included in the mouth for five subjects A to E, and the amount of saliva secretion was measured.

  Subject A is a male in his 50s, subject B is in his 60s, subject C is in his 40s, subject D is in his 50s, and subject E is in his 50s. These subjects A to E are all those with dry mouth symptoms. In particular, subject E is a person who is undergoing treatment with an anticancer agent after surgery for tongue cancer, and is normally in a state in which little saliva is secreted.

  About each of these subjects A to E, sample tablets composed of the components shown in Tables 1 and 2 above were included in the mouth for 1 minute, and saliva accumulated in the oral cavity was discharged into a measuring cup and the amount thereof was measured. Each sample tablet is composed of a 500 mg tablet, and each component shown in Table 1 is contained in% consisting of the numerical values in the table, and the remainder is composed of a starch component such as dextrin.

  Comparative Example 1 is a so-called bulk sample in which a sample tablet is simply composed of dextrin. In Comparative Examples 2 to 3, the only component that promotes salivation is sodium bicarbonate, and the contents are different from each other. In Comparative Examples 4 to 7, the only component that promotes salivation is phosphorylated oligosaccharide calcium, which is configured with different contents. In Comparative Examples 8 to 10, the only component that promotes saliva secretion is lactoferrin, and the contents thereof are different from each other.

  In these Comparative Examples 2 to 10, there was a tendency that the amount of saliva secretion increased in all subjects A to E as the content of the components increased.

  Inventive Examples 1 to 14 all fall within the range defined in the present invention. For example, Invention Example 3 has 16% sodium bicarbonate, 10% phosphorylated oligosaccharide calcium, and 1% lactoferrin, while Comparative Example 3 has only 16% sodium bicarbonate, Comparative Example 6. Shows only 10% phosphorylated oligosaccharide calcium, and Comparative Example 10 contains only 1% lactoferrin. Since Example 3 of the present invention exceeds the total saliva secretion amount of Comparative Examples 3, 6, and 10, a synergistic effect is exhibited by mixing these components into one composition. Conceivable.

  In Comparative Example 11 and Invention Examples 1-6, sodium bicarbonate was fixed at 16% and lactoferrin was fixed at 1%, and the content of phosphorylated oligosaccharide calcium was varied, and the amount of saliva secreted respectively. It is the result of having measured. In each of Invention Examples 1 to 6, since phosphorylated oligosaccharide calcium was included in the range of 1 to 30%, the total amount of saliva secretion for five subjects exceeded 150 ml. In Comparative Example 11, since the phosphorylated oligosaccharide calcium exceeds 30%, the amount of saliva secretion tends to be lower than those of Invention Examples 5 and 6, and when the phosphorylated oligosaccharide calcium exceeds 30%, the raw material Cost burden increases. In addition to this, since several of the subjects who took this Comparative Example 11 complained of symptoms such as looseness of the stomach, the disadvantages of adding too much phosphorylated oligosaccharide calcium have appeared. End up.

  Invention Examples 9 to 13 are examples in which the composition is composed only of phosphorylated oligosaccharide calcium and lactoferrin without adding sodium bicarbonate. In the present invention examples 9 to 13 as well, since the total saliva secretion amount of Comparative Examples 4 and 8 is exceeded, a synergistic effect by mixing these components into one composition appears. It is considered a thing.

  In Inventive Example 8, the contents of phosphorylated oligosaccharide calcium and lactoferrin are the same as in Inventive Example 7, but the content of sodium bicarbonate exceeds 25% by setting the sodium bicarbonate content to 25%. It is set as follows. It has been shown that salivary secretion can be further increased by increasing the content of sodium bicarbonate. In Example 8 of the present invention, the saliva secretion amount can be increased in this way. Although no particular report was made from the subject this time, one of the subjects who took Example 8 of the present invention complained of symptoms such as slight nausea, so this sodium bicarbonate was added. Disadvantages due to being too much will appear.

  Invention Example 14 is an example in which 2% of potassium carbonate was further added. It can be seen that the amount of saliva secreted can be dramatically increased by adding potassium carbonate.

Inventive Example 15 is an example in which magnesium carbonate contained 3% in terms of magnesium in addition to the contents of phosphorylated oligosaccharide calcium and lactoferrin shown in Inventive Example 11. In Example 15 of the present invention, the amount of saliva secreted is increased in the amount of magnesium carbonate added.

  Invention Example 16 is an example containing 3% sucralose in addition to the contents of phosphorylated oligosaccharide calcium and lactoferrin shown in Invention Example 11. In Example 16 of the present invention, the amount of saliva secreted is increased by the amount of sucralose added.

  An eye drop solution containing an eye drop component and an auxiliary component was prepared. The auxiliary component is composed of 2.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 16% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. In addition, as in the case of Santen Medical 10 (registered trademark) of Santen Pharmaceutical, the eye drop component is in mass% with respect to the total amount of the eye drop component, vitamin B12 (cyanocobalamin) 0.02%, neostigmine methyl sulfate 0.005%, vitamin B6 (pyridoxine hydrochloride) Salt) 0.05%, panthenol 0.05%, potassium L-aspartate 1.0%, taurine 1.0%, chlorpheniramine maleate 0.03%, epsilon-aminocaproic acid 1.0%, dipotassium glycyrrhizinate, tetrahydrozoline hydrochloride 0.03% In addition, sodium edetate hydrate, chlorobutanol, benzalkonium chloride solution, boric acid, d-borneol, l-menthol, and a pH regulator are added. The rest of the eye drop component is moisture.

  When such an eye drop component was instilled into a subject having dry eye symptoms, there was a reply that dry eye symptoms had recovered from before.

  In addition, as an auxiliary component, it is composed of 16% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the remainder is composed of water in mass% with respect to the total mass of the auxiliary component. An example of the eye drop component composed of only water was also tested by the same test subject, but there was a reply that dry eye symptoms were recovered from the same problem.

  A nasal solution containing a nasal spray component and an auxiliary component was prepared. The auxiliary component is composed of 3.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of phosphorylated oligosaccharide calcium 6%, lactoferrin 2.5%, and the balance being moisture. The nasal spray component contains 0.5 mg of naphazoline hydrochloride, 5 mg of chlorpheniramine maleate, 3 mg of lidocaine hydrochloride, and 0.2 mg of benzethonium chloride in 1 ml as in the case of New Lulu (registered trademark) nasal spray. , Tonicity agents, parabens, and pH regulators are added.

  Due to the improvement of brain function from the clinical trial that the nasal spray component was noseed to the subject, the behavior that seemed to have acted on the parasympathetic nerve was calmed down, and the dry eye was improved and the field of view was expanded. There was a reply that symptoms that seemed to be effective had recovered from before.

In addition, as auxiliary components, it is composed of 6% phosphorylated oligosaccharide calcium, 2.5% lactoferrin, and the remainder with water in mass% with respect to the total mass of auxiliary components. The same test subject was also tested in the case where the nasal spray component was composed of only water, but there was a reply that symptoms such as dry eye and widening of the visual field were recovered from the previous time.
In addition, a nasal solution containing a nasal spray component consisting of a product name (Nazar (registered trademark)) manufactured by Sato Pharmaceutical Co., Ltd. and an auxiliary component was prepared. The auxiliary component is composed of 3.6% liquid by mass% with respect to the total mass of the eye drop solution. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of phosphorylated oligosaccharide calcium 6%, lactoferrin 2.5%, and the balance being moisture. When this was dropped on the subject, there was a similar answer.

  A cosmetic containing a cosmetic ingredient and an auxiliary ingredient was prepared. The auxiliary component is composed of 5.2% liquid by mass% with respect to the total mass of the cosmetic. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. In addition, the cosmetic ingredients are in% by weight of the total cosmetic ingredients, whitening ingredients (L-ascorbic acid 2-glucoside, etc.) 2.00%, rough skin prevention ingredients (glycyrrhizic acid 2K): 0.10%, moisturizing ingredients ( Concentrated glycerin: 8.00%, trehalose solution: 1.00%, sodium hyaluronate: 0.05%, oily emollient component (soybean oil) 0.03%, pH adjuster: 0.03%, thickener ( Xanthan gum: 0.30%, hydroxyethylcellulose 0.30%), solubilizer (polyoxyethylene hydrogenated castor oil): 0.5%, preservative (methylparaben: 0.21%, phenoxyethanol: 0.11%), Chelating agent (EDTA-2Na): 0.10%, natural vitamin E: 0.07%, balance: purified water is added.

  When such a cosmetic was applied to a subject, there was a reply that symptoms of rough skin, dullness, and dry skin were recovered from before.

Further, as an auxiliary component, it is composed of 12% of phosphorylated oligosaccharide calcium, 1% of lactoferrin, and the remainder is composed of water in terms of mass% with respect to the total mass of the auxiliary component. In addition, although the same test subject was also tested in the case where the cosmetic component was composed only of moisture, there was a response that the symptoms of rough skin and dullness were recovered from the previous time.
In addition to the above-mentioned components, a cosmetic containing a cosmetic ingredient made of ROHTO Pharmaceutical Co., Ltd. (trade name) (medicinal gokujun (registered trademark)) and an auxiliary ingredient was prepared. The auxiliary component is composed of 5.2% liquid by mass% with respect to the total mass of the cosmetic. This auxiliary component is mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 1% lactoferrin, and the balance being moisture. When such a cosmetic was applied to a subject, there was a reply that symptoms of rough skin, dullness, and dry skin were recovered from before.

  A tablet containing a drug component and an auxiliary component was prepared. The auxiliary component is 2.3% by mass with respect to the total mass of the tablet, and covers the surface of the drug component. This auxiliary component is mass% with respect to the total mass of the auxiliary component, 7% phosphorylated oligosaccharide calcium, 3% lactoferrin, and the remainder is composed of starch. The drug component is the mass% of the total drug component, and the components in 9 tablets are Takadiastase N1: 150 mg, Lipase AP12: 60 mg, Akamegasiwa extract: 63 mg, Licorice powder: 150 mg, Magnesium aluminate 720 mg, Synthetic hydrotalcite 300 mg, magnesium hydroxide 600 mg, funnel extract 30 mg, powdered powder 105 mg, keihi powder 225 mg, fennel powder 60 mg, clove powder 30 mg, ginger powder 75 mg, I-menthol 9 mg. When such a tablet was swallowed by a test subject, not only was the gastrointestinal condition improved, but the amount of saliva secreted when included in the mouth could be increased, and it was answered that it was easier to drink there were.

  Similarly, powders and granules were prepared with the same ingredients as the tablet described above and applied to the subjects.

  A cleansing composition (shampoo) for skin or hair containing a cleaning component and an auxiliary component was prepared. The auxiliary component is 5.6% in terms of mass% with respect to the total mass of the shampoo. This auxiliary component is in mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 2% lactoferrin, and the balance is moisture. Ingredients for cleaning are mass% of total cleaning ingredients, water: 53.3%, surfactant (soap): 42.0%, foaming agent: 3.0%, fragrance: 0.5%, preservative: less than 0.5%, pH adjustment Contains: 0.5%, conditioning agent: 0.5%. When such a shampoo was used to wash the hair of the subjects, there was a reply that dandruff was improved and that the hair was shiny.

  A hair treatment material (rinse) containing a hair treatment component and an auxiliary component was prepared. The auxiliary component is 7.1% by mass% with respect to the total mass of the rinse. This auxiliary component is in mass% with respect to the total mass of the auxiliary component, and is composed of 12% phosphorylated oligosaccharide calcium, 2% lactoferrin, and the balance is moisture. The hair treatment component is the mass% of the total hair treatment component, myristyl alcohol: 5.00%, dimethicone: 1.00%, ethylhexyl isononanoate: 1.00%, (stearoxymethicone / dimethicone) copolymer: 0.50%, hydrogenated olive oil: 0.50%, diisobutyl adipate: 0.25%, diisopropyl adipate: 0.25%, lavender oil: 0.03%, glycerin: 5.00%, glycine: 1.00%, dilauroyl glutamate (cholesteryl / octyldodecyl): 0.20%, stearamide ethyl diethylamine : 3.00%, cocoyl arginine ethyl PCA: 0.20%, hydrolyzed silk: 0.01%, glycolic acid: 0.63%, hydrogenated lecithin: 0.50%, ethanol: 0.01%, the balance being water. When such a rinse was used to wash the hair of the subjects, there was a reply that dandruff was improved and that the hair was shiny.

  A jelly confectionery containing an edible ingredient and an auxiliary ingredient was prepared. The auxiliary component is 3.1% by mass% with respect to the total mass of the confectionery. This auxiliary component is mass% with respect to the total mass of the auxiliary component, 16% phosphorylated oligosaccharide calcium, 6% lactoferrin, and the balance is moisture. The edible component consists of 82.3 g of water, 2.3 g of protein, 15.3 g of sugar, 0.1 g of fiber, and 3 mg of calcium in 100 g. When such a jelly confectionery was eaten by a subject, there was a reply that a large amount of saliva was promoted.

  A beverage composition containing a beverage component and an auxiliary component made of “Southern Alps Natural Water” (registered trademark) manufactured by Suntory Ltd. was prepared. The auxiliary component is 10% by mass% with respect to the total mass of the beverage composition. This auxiliary component is mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium 12%, lactoferrin 4%, and the balance is moisture. In addition, the beverage component is “Southern Alps Natural Water” (registered trademark) manufactured by Suntory Ltd., sodium: 0.4 to 1.0 mg, calcium: 0.6 to 1.5 mg, magnesium: 0.1 to 0.3 mg, potassium: 0.1 to 0.5 mg, Hardness: 30 and pH: about 7. When such a drink was allowed to be drunk by a subject, there was a reply that a large amount of saliva was promoted.

  The seasoning containing the seasoning component and auxiliary component which consist of soy sauce by Kikkoman Co., Ltd. was produced. The auxiliary component is 5% by mass% based on the total mass of the seasoning. This auxiliary component is mass% with respect to the total mass of the auxiliary component, phosphorylated oligosaccharide calcium 12%, lactoferrin 4%, and the balance is moisture. The seasoning ingredients are soy sauce manufactured by Kikkoman Corporation. When such a seasoning was used by the test subject, there was a reply that the taste was mild.

  As shown in Table 1, the sample tablets obtained for conducting the experimental study on the tooth pain relieving agent were included in the mouth of the subject, and the effect of relieving tooth pain was heard through an interview.

  Sample tablets were prepared by mixing the auxiliary components shown in Table 3 below and the main components. The numerical values in Table 3 are expressed in mass% with respect to the total mass.

  The test subject was a male in his 50s, and in the diagnosis of a dentist, the caries reached the pulp in the lower first premolar and received a diagnosis of C3. In addition, interviews with subjects prior to the experiment confirmed that they had subjective symptoms of toothache.

  The subject was asked to bite the sample tablet through the lower first premolar with caries for 10 minutes, and the pain relief effect was evaluated over 5 levels. It is determined that the closer the relaxation effect in the table is to 5, the greater the relaxation effect and the more the toothache was cured. On the other hand, the closer the relaxation effect in the table is to 1, the smaller the relaxation effect, and it is judged that the toothache is hardly cured.

  Each sample tablet is composed of a 500 mg tablet, and each component shown in Table 1 is contained in% consisting of the numerical values in the table, and the remainder is composed of a starch component such as dextrin.

  In Comparative Example 1, the sample tablet was simply composed of phosphorylated oligosaccharide calcium, but the effect of alleviating toothache was small. Similarly, in Comparative Example 2, the sample tablet was composed only of lactoferrin, but the effect of alleviating toothache was small.

  On the other hand, Examples 17-19 of the present invention consist of phosphorylated oligosaccharide calcium and lactoferrin at a content ratio within the range defined in the present invention, but reported to have a greater relief effect on toothache than the subject. It was done.

  In addition, Examples 20 to 22 of the present invention consist of phosphorylated oligosaccharide calcium and lactoferrin with a content ratio within the range specified in the present invention, and further, lactoperoxidase with a content ratio within the range specified in the present invention. However, a greater relief of toothache was reported than the subject. However, although the comparative example 14 comprised the content of lactoperoxidase with more than 20%, the effect was somewhat saturated.

1 Nucleating agent 2 Auxiliary ingredient 10 Tablet

Claims (28)

Contains eye drop ingredients and auxiliary ingredients,
The said auxiliary component is the mass% with respect to the said auxiliary component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%. The ophthalmic solution according to claim 1, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% with respect to the total mass of the ophthalmic solution. 3. The ophthalmic solution according to claim 1, wherein the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component are stored in advance in different containers and can be separately instilled. Containing a nasal drug component and an auxiliary component,
The said auxiliary component is the mass% with respect to the said auxiliary component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%. The nasal solution according to claim 4, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% with respect to the total mass of the nasal solution. The nasal spray solution according to claim 4 or 5, wherein the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component are stored in different containers in advance and can be separately nasalized. Contains cosmetic ingredients and auxiliary ingredients,
Cosmetics characterized in that the auxiliary component is in mass% with respect to the total mass of the auxiliary component and contains phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10%. The cosmetic according to claim 7, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the cosmetic. The cosmetic according to claim 7 or 8, wherein the phosphorylated oligosaccharide calcium and the lactoferrin in the auxiliary component are stored in advance in different containers and can be treated separately. Contains pharmaceutical ingredients and auxiliary ingredients,
The said auxiliary component is the mass% with respect to the said auxiliary component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%. The tablet characterized by the above-mentioned. The tablet according to claim 10, wherein the auxiliary component is coated on the surface of a nucleating agent containing the drug component. The tablet according to claim 10 or 11, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the tablet. Both contain a drug component consisting of powder or granules, and an auxiliary component,
The auxiliary component is a powder or granular drug characterized by containing phosphorylated oligosaccharide calcium: 1 to 30% and lactoferrin: 0.01 to 10% in mass% with respect to the total mass of the auxiliary component. The powder or granular drug according to claim 13, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the powder or granular drug. Contains cleaning ingredients and auxiliary ingredients,
The above-mentioned auxiliary component is a mass% with respect to the total mass of the auxiliary component and contains phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%. . 16. The skin or hair cleaning composition according to claim 15, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass based on the total mass of the skin or hair cleaning composition. Contains hair treatment ingredients and auxiliary ingredients,
The said auxiliary | assistant component is the mass% with respect to the said auxiliary | assistant component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%, The hair treatment material characterized by the above-mentioned. The hair treatment material according to claim 17, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the hair treatment material. Contains edible ingredients and auxiliary ingredients,
The said auxiliary | assistant component is the mass% with respect to the said auxiliary | assistant component total mass, Phosphorylated oligosaccharide calcium: 1-30%, Lactoferrin: 0.01-10%, The food composition characterized by the above-mentioned. 20. The food composition according to claim 19, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the food composition. Contains beverage ingredients and auxiliary ingredients,
The said auxiliary | assistant component is the mass% with respect to the said auxiliary | assistant component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%. The drink composition characterized by the above-mentioned. The beverage composition according to claim 21, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% based on the total mass of the beverage composition. Contains seasoning ingredients and auxiliary ingredients,
The said auxiliary | assistant component is the mass% with respect to the said auxiliary | assistant component total mass, and contains phosphorylated oligosaccharide calcium: 1-30%, lactoferrin: 0.01-10%, The seasoning composition characterized by the above-mentioned. 24. The seasoning composition according to claim 23, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% relative to the total mass of the seasoning composition. In an oral care composition that promotes oral health by including in the oral cavity,
% By weight relative to the total weight of the composition,
Phosphorylated oligosaccharide calcium: 1-30%
Lactoferrin: 0.01-10%
Magnesium compound: An oral care composition comprising 1 to 5% in terms of magnesium. In an oral care composition that promotes oral health by including in the oral cavity,
% By weight relative to the total weight of the composition,
Phosphorylated oligosaccharide calcium: 1-30%
Lactoferrin: 0.01-10%
Oral care composition characterized by containing sucralose: 1 to 5%. Contains auxiliary ingredients,
The auxiliary component is characterized by containing phosphorylated oligosaccharide calcium: 1 to 30%, lactoferrin: 0.01 to 10%, and lactoperoxidase: 1 to 20% in mass% based on the total mass of the auxiliary component. Tooth pain relieving agent. 28. The tooth pain relieving agent according to claim 27, wherein the auxiliary component is contained in an amount of 0.1 to 100% by mass% relative to the total mass of the tooth pain relieving agent.

Images